Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00936520
Other study ID # NA_00029830
Secondary ID
Status Terminated
Phase Phase 1
First received July 9, 2009
Last updated May 9, 2017
Start date August 2009
Est. completion date May 2010

Study information

Verified date May 2017
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with escalating concentrations of the study drug for approximately 1 week.


Description:

SAR 1118 is a potent and selective small molecule lymphocyte function antigen-1 (LFA-1) antagonist and may be therapeutically useful as a novel topical anti-inflammatory agent in a wide variety of ocular inflammatory conditions including diabetic retinopathy and diabetic macular edema. Recent evidence has demonstrated that topically delivered SAR 1118 ophthalmic solution can be detected in the aqueous, vitreous, and retina 4 to 12 hours after dosing at potentially therapeutic levels in animal models. However, the ability for the current sterile ophthalmic formulation of SAR 1118 to penetrate in sufficiently high therapeutic concentrations into the anterior and posterior chamber in humans is unknown.


Recruitment information / eligibility

Status Terminated
Enrollment 30
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Human subjects meeting the following criteria will be enrolled:

- Age =18 years

- BCVA =20/40 in the study eye (BCVA measured at 4M ETDRS)

- Male or female

- Current non-smoker (last date of smoking should be at least 60 days before study enrollment)

- Surgically eligible to undergo elective PPV including, but not limited to, epiretinal membrane, vitreomacular traction, macular holes, or retinal detachment. The elective surgery must be able to be scheduled at least 21 days in advance to allow time for screening and for initiation of study drugs.

- Females must be non-pregnant, non-lactating, surgically sterile for at least 3 months, post-menopausal for at least 1 years with follicle stimulating hormone (FSH) greater than or equal to 40 mIU/mL, or willing to use an approved method of contraception from 35 days prior to first study drug administration. Approved methods of contraception include: a non-hormonal intrauterine device (IUD) with spermicide, a female condom with spermicide, a diaphragm with spermicide, a cervical cap with spermicide, use of a condom with spermicide by sexual partner or sterile sexual partner.

- Willing and able to provide written informed consent after the nature of the study has been explained, and prior to any research-related procedures.

- Willing and able to comply with all study procedures including follow-up instructions

Exclusion Criteria:

- Individuals not eligible to participate in this study include those who meet any of the following criteria:

- Vitreous hemorrhage

- Active retinal detachment

- Autoimmune disease of the anterior segment or posterior chamber including chronic keratoconjunctivitis sicca, uveitis, iritis/scleritis, blepharitis of either eye

- Glaucoma requiring topical medications, infectious conjunctivitis, keratitis, or endophthalmitis of either eye

- Prior vitrectomy or intraocular lens placement, within 90 days of Day 0

- Previous intravitreal drug delivery administered in the study eye within the following time period of Day 0:

- Intravitreal steroid given =3 months

- Intravitreal vascular endothelial growth factor inhibitors given =2 months

- Previous participation in any studies of investigational drugs within 1 month preceding Day 0

- Any concurrent ophthalmic over-the-counter or topical ocular pharmaceutical within 30 days of Day 0 with the exception of saline tear lubricant.

- History of malignancy, renal insufficiency, or hepatic insufficiency

- Positive serum pregnancy test

- Use of any oral, implantable, or injectable contraceptive within 30 days or 5 half-lives of the contraceptive (whichever is longer) prior to first study drug administration; patients must refrain from these types of contraceptives during the treatment period and may resume the use of such contraceptives following the 1-week observation period.

- Any history of excessive alcohol (as judged by the Investigator) or illicit drug use/abuse

- Consumption of any alcohol or any illicit drugs within one week of first study drug administration

- Use of any tobacco or nicotine-containing products within 2 months prior to first study drug administration

- Any laboratory abnormality considered clinically significant by the Investigators

- Subjects with a hemoglobin < 12.0 g/dL

- Any clinically significant acute or chronic medical condition that would preclude participation in a clinical study

- Any history of autoimmune disease, immunodeficiency disorder, positive HIV, acute hepatitis A (IgM positive), or hepatitis B, or C, or organ or bone marrow transplant

- Participation in an ongoing investigational drug or medical device study

Study Design


Intervention

Drug:
SAR 1118 0.1%
Daily eye drops (twice daily, ~50 microliter [uL] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
SAR 1118 1.0%
Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
SAR 1118 5.0%
Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days

Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University SARcode Bioscience

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary outcome variable: frequency of ocular and non-ocular adverse events judged related to administration of SAR 1118 Ophthalmic Solution, or of inability to tolerate the medication. 35 days
Secondary Secondary outcome variable: concentrations of SAR 1118 in aqueous and vitreous on the day of vitrectomy. day 9
See also
  Status Clinical Trial Phase
Completed NCT01702441 - Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema Phase 1/Phase 2
Active, not recruiting NCT04543331 - Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Completed NCT02424019 - Phase 4 IOP Signals Associated With ILUVIEN® Phase 4
Completed NCT02633852 - Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Phase 4
Completed NCT04857996 - Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) Phase 2
Recruiting NCT05919693 - A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) Phase 1/Phase 2
Completed NCT04739306 - Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema Phase 3
Recruiting NCT06116916 - Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema Phase 2
Completed NCT02050828 - The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema Phase 2
Recruiting NCT03859245 - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention N/A
Completed NCT02585401 - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada N/A
Terminated NCT02080091 - Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies N/A
Terminated NCT04697758 - Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema Phase 1/Phase 2
Not yet recruiting NCT06398080 - An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Active, not recruiting NCT05989126 - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) Phase 3